Clinical Study Of Baoshen Paidu Decoction Delaying The Progression Of Renal Function In Chronic Kidney Disease Stage 2-3

Objective:To evaluate the efficacy and safety of baoshenpaidu decoction on renal function and clinical symptom scores of patients with chronic kidney disease(CKD2-3)through prospective randomized controlled trial,and to provide a basis for further guiding the clinical treatment practice of traditional Chinese medicine.Methods:This study collected cases from February 2019 to December,see a doctor in the Shanxi Provincial Hospital of Traditional Chinese Medicine nephrology outpatient or inpatient ward,diagnosed with chronic kidney disease(CKD2-3)phase wet(spleen and kidney deficiency,blood stasis syndrome)patients with traditional Chinese and western medicine into standard.A total of 91 cases were selected according to the principle of random control.They were divided into treatment group(47 cases)and control group(44 cases).Both groups were given general treatment,On the basis of general treatment,the treatment group and the control group were given baoshenpaidu formula and Niaoduqing granules.After 8 weeks treatment,8 weekend compared two groups of patients with symptoms of change,we assessed the TCM symptom integral and renal function(creatinine,uric acid,urea nitrogen),24 h urine protein quantitative,electrolyte(potassium,calcium,phosphorus),hemoglobin,blood lipid(triglyceride,cholesterol)laboratory indexes such as observation,judging curative effects.Results: Total efficacy evaluation: the effective rate of the treatment group was 85.11%,which was better than 70.45 in the control group(P<0.05).Efficacy evaluation of TCM syndromes: the effective rate of the treatment group was 85.11%,which was better than the effective rate of the control group by 75%(P<0.05).Total score of TCM syndromes: after treatment,the two groups have a significant downward trend(P <0.05),and the treatment group is significantly better than the control group after 8 weeks(P<0.05),which is statistically significant;Renal function: creatinine,urea nitrogen and uric acid in the two groups decreased significantly after treatment compared with before treatment(P<0.01),and the decline in the treatment group was better than that in the control group after 8 weeks(P<0.05).After 8 weeks of treatment,the 24 h urinary protein decreased compared with the previous one.After 8 weeks,the decline in the treatment group was better than that in the control group(P <0.05).There was no significant change in hemoglobin,blood lipid and electrolyte before and after reatment(P>0.05),there was no significant ifference,and there was no statistical difference.Conclusion:Boshenpaidu ecoction can significantly improve the clinical symptoms of patients with spleen-kidney qi deficiency and damp-heart and blood stasis type in CKD2-3 stage,and improve the quality of life of the patients.Boshenpaidu ecoction can reduce the renal function level of patients with spleen-kidney qi deficiency and dampened blood stasis in stage 2-3 and delay the progress of CKD.